ERCC1Asn118Asn(C／T)基因多态性与进展期胃癌铂类药物化疗敏感性的Meta分析

Association between Asn118Asn(C/T ) polymorphism of ERCC 1 gene and sensitivity to platinumbased chemotherapy in advanced gastric cancer: a meta-analysis

目的：综合评价胃癌患者中切除修复交叉互补基因1（excision repair cross complementing1，ERCC1）Asn118Asn（C／T）基因多态性与铂类药物化疗敏感性的关系。方法：计算机检索PubMed、EMBASE、中文科技期刊数据库、中国生物医学文献数据库、中国期刊全文数据库和万方数据库，收集有关进展期胃癌患者ERCCl Asnll8Asn（C／T）基因多态性与铂类药物化疗敏感性的相关研究文献，以临床化疗有效率（完全缓解＋部分缓解）作为化疗敏感评价指标，采用RevMan5．2及Stata12．0软件进行统计学分析，计算合并比值比（oddratio，OR）及95％可信区间（confidence interval，CI）。结果：本研究共纳入9篇文献，共计病例数942例。Meta分析结果显示，各基因型间（CT vs CC：OR：0．42，95％CI为0．27～0．66；TT vs CC：OR=0．46，95％CI为0．26～0．81；CT＋TTVSCC：OR=0．52，95％CI为0.39～0．70）、亚洲人群亚组（CT＋TT vs CC：OR：0．51，95％CI为0.36～0．72）以及欧洲人群亚组（CT＋TT vs CC：OR=0．56，95％CI为0．32～0．97）中职CC1Asn118Asn基因多态性与进展期胃癌对铂类化疗药物敏感性的差异有统计学意义。结论：ERCC1Asn118Asn（C／T）基因多态性可能与胃癌铂类化疗药物耐药性相关。

Objective： To quantitatively evaluate the association between Asn118Asn （C/T） polymorphism of excision repair cross complementing 1 （ERCC1） gene and sensitivity to platinum- based chemotherapy in advanced gastric cancer. Methods： The relevant published studies were retrieved from PubMed, EMBASE, Chinese Science and Technology Periodicals Data, Chinese Biomedical Literature Data, China National Knowledge Infrastructure and Wanfang databases with computer. Clinical response [complete response （CR） ＋ partial response （PR）] was employed to estimate chemosensitivity. Odds ratio （OR） and its 95% confidence interval （CI） were calculated. The statistical analysis was conducted by RevMan 5.2 and Stata12.0 softwares. Results： A total of 942 cases from 9 trials were included in this analysis. The result of Meta-analysis showed the statistical significance was found between ERCC1Asn118Asn （C/T） polymorphism and clinical response in all genotypes （CT vs CC： OR = 0,42, 95% CI： 0.27-0.66; TT vs CC： OR = 0.46, 95% CI： 0.26-0.81; CT＋TT vs CC： OR = 0.52, 95% CI： 0.39-0.70） including Asian subgroup （CT＋TT vs CC： OR = 0.51, 95% CI： 0.36-0.72） and European subgroup （CT＋TT vs CC： OR = 0.56, 95% CI： 0.32-0.97）. Conclusion： In this Meta-analysis, polymorphism of ERCC1Asnl 1 8Asn （C/T） may be associated with non-response to platinum-based chemotherapy in advanced gastric cancer.